GSK Spinout NeRRe Begins with $19M, Neurokinin Drugs
By Nuala Moran
Friday, December 21, 2012
A third spinout has emerged from GlaxoSmithKline plc's neurosciences research portfolio, with the formation of NeRRe Therapeutics Ltd. The new company begins life with a portfolio of four neurokinin-1 receptor antagonists of which two are ready for Phase II.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.